Sandler, R. S., S. Halabi, J. A. Baron, S. Budinger, E. Paskett, R. Keresztes, N. Petrelli, M. Pipas, D. D. Karp, C. L. Loprinzi, G. Steinbach, and R. Schilsky. 2003. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. New England Journal of Medicine 348(10):883–890.
Shaw, E., R. Arusell, B. Scheithauer, J. O’Fallon, B. O’Neill, R. Dinapoli, D. Nelson, J. Earle, C. Jones, T. Cascino, D. Nichols, R. Ivnik, R. Hellman, W. Curran, and R. Abrams. 2002. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: Initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. Journal of Clinical Oncology 20(9):2267–2276.
Somkin, C. P., A. Altschuler, L. Ackerson, A. M. Geiger, S. M. Greene, J. Mouchawar, J. Holup, L. Fehrenbacher, A. Nelson, A. Glass, J. Polikoff, S. Tishler, C. Schmidt, T. Field, and E. Wagner. 2005. Organizational barriers to physician participation in cancer clinical trials. The American Journal of Managed Care 11(7):413–421.
Steensma, D. P. 2009. The ordinary miracle of cancer clinical trials. Journal of Clinical Oncology 27(11):1737–1739.
Strauss, G. M., J. Herndon, M. A. Maddaus, D. W. Johnstone, E. A. Johnson, D. M. Watson, D. J. Sugarbaker, R. L. Schilsky, and M. R. Green. 2004. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage 1B non-small cell lung cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633. Journal of Clinical Oncology 22(14 Suppl.):7019.
Thompson, I. M., P. J. Goodman, C. M. Tangen, M. S. Lucia, G. J. Miller, L. G. Ford, M. M. Lieber, R. D. Cespedes, J. Atkins, S. M. Lippman, S. M. Carlin, A. Ryan, C. M. Szczepanek, J. Crowley, and C. A. Coltman. 2003. The influence of finasteride on the development of prostate cancer. New England Journal of Medicine 349(3):215–224.
Vogel, V., J. P. Costantino, D. L. Wickerham, M. Cronin, R. S. Cecchini, J. Atkins, T. B. Bevers, L. Fehrenbacher, E. R. Pajon, J. L. Wade III, A. Robidoux, R. Margolese, J. James, S. M. Lippman, C. D. Runowicz, P. A. Ganz, S. E. Reis, W. McCaskill-Stevens, L. G. Ford, V. C. Jordan, and N. Wolmark. 2006. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial. Journal of the American Medical Association 295:2727–2741.
Whitney, C., W. Sause, B. Bundy, J. H. Malfetano, E. V. Hannigan, W. C. Fowler, Jr., D. L. Clarke-Pearson, and S. Y. Liao. 1999. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: A Gynecologic Oncology Group and Southwest Oncology Group study. Journal of Clinical Oncology 17(5):1339–1348.
Wickerham, D. L., M. J. O’Connell, J. P. Costantino, W. M. Cronin, S. Paik, C. E. Geyer, P. A. Ganz, N. Petrelli, E. P. Mamounas, T. B. Julian, and N. Wolmark. 2008. The half century of clinical trials of the National Surgical Adjuvant Breast and Bowel Project. Seminars in Oncology 35(5):522–529.
Winton, T., R. B. Livingston, D. Johnson, J. Rigas, M. Johnston, C. Butts, Y. Cormier, G. Goss, R. Inculet, E. Vallieres, W. Fry, D. Bethune, J. Ayoub, K. Ding, L. Seymour, B. Graham, M.-S. Tsao, D. Gandara, K. Kesler, T. Demmy, and F. Shepherd. 2005. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. New England Journal of Medicine 352(25):2589–2597.
Woodcock, J. 2009. FDA Perspective on Evidence for Regulatory Approval in Cancer. Presented at the National Cancer Policy Forum workshop on Assessing and Improving the Value in Cancer Care, February 9, 2009, Washington, DC.
Zubrod, C. G. 1984. Origins and development of chemotherapy research at the National Cancer Institute. Cancer Treatment Reports 68(1):9–19.